LB Pharmaceuticals Inc Common Stock
LBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.38B
Close$
$9.75
78% downside
Current Fair Value
78% downsideOvervalued by 78% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.38 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | 0.42 |
| Outstanding Shares | 28,241,701 |
Return
| Return on Equity | -12.74% |
|---|---|
| Return on Assets | -12.27% |
| Return on Invested Capital | -14.04% |
Valuation & Multiples
| P/E Ratio | -2.24 |
|---|---|
| PEG | -6.51 |
| Price to Sales | - |
| Price to Book Ratio | 3.41 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -19.72 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.95
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.01%▼ 96.50% |
|---|---|
| Total Invested | $137.54M▼ 80.14% |
| Investors Holding | 29▼ 48.00% |
ESG Score
No data
About LB Pharmaceuticals Inc Common Stock
16 employees
CEO: Heather D. Turner Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.